.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The mammalian circadian clock functions as a sophisticated molecular timer. At its core, a negative feedback loop involves the transcription factors CLOCK and BMAL1. These factors drive the expression of Period (PER) and Cryptochrome (CRY) proteins. However, the precise timing of this loop depends on the circadian kinase CK1δ. Recent evidence suggests that the nuclear availability of CK1δ is a major factor in determining the length of the circadian period. Researchers have found that the cell strictly limits the amount of this kinase in the nucleus through rapid degradation and active export.
Moreover, the circadian kinase CK1δ regulates how PER and CRY proteins interact within the cell. Specifically, phosphorylation mediated by this kinase can disrupt the interaction between PER2 and CRY1. This disruption leads to the accumulation of PER2 in the cytoplasm during the later stages of the circadian cycle. Consequently, CRY1 is released and accumulates in the nucleus. This transition is essential for sustaining the repression of CLOCK:BMAL1 on the DNA. Therefore, CK1δ acts as a molecular switch that supports the transition from the early to the late repressive phase of the clock.
Understanding these molecular pathways is vital for clinical practice in India. Circadian disruptions often lead to sleep disorders, metabolic syndromes, and psychiatric conditions. For instance, mutations in the genes regulating PER2 stability can result in Familial Advanced Sleep Phase Syndrome. Additionally, the clearing of nuclear PER2 and the release of CRY1 ensure that the clock remains synchronized with environmental cues. Future therapies targeting CK1δ could potentially help manage jet lag, shift work disorders, and even type 2 diabetes. Furthermore, clinicians can use this knowledge to better understand the chronobiology of their patients.
CK1δ regulates the stability and localization of PER proteins, effectively timing the transition between different phases of transcriptional repression in the biological clock.
The cell limits nuclear CK1δ through rapid degradation and active export of the kinase when it is not part of a protein complex, ensuring the clock runs at the correct speed.
Dissociation allows CRY1 to enter the nucleus and sustain the inhibition of gene transcription, which is necessary for the proper progression of the 24-hour cycle.
Disclaimer: This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Serrano FE et al. Nuclear CK1δ as a critical determinant of PER:CRY complex dynamics and circadian period. Elife. 2026 Jun 15. doi: undefined. PMID: 42290481.
Toh KL et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science. 2001;291(5506):1040-1043.
Narasimamurthy R, Virshup DM. The phosphorylation switch that regulates the mammalian circadian clock. Bioessays. 2021;43(1):e2000211.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new study reveals that nuclear CK1δ is a critical determinant of the circadian period. By modulating the dynamics of the PER:CRY complex, this kinase manages the transition between repressive phases in the biological clock, providing a deeper understanding of sleep and metabolic rhythms.
2 months ago
A new case study illuminates how functional connectivity changes drive recovery from pure alexia following posterior cerebral artery infarction. Functional reorganization supports reading recovery despite permanent structural tract disconnection, highlighting key implications for stroke rehabilitation.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
